LUGPA Policy Brief - Commerce Defines Zero-Tariff Exemptions for Certain Specialty Pharmaceuticals

October 2026

At a Glance

What Happened:
The U.S. Department of Commerce published guidance implementing provisions of Presidential Proclamation 11020, which established Section 232 tariffs on certain imported pharmaceuticals and pharmaceutical ingredients. The notice identifies specialty pharmaceutical products that may qualify for a 0% tariff rate and establishes a process for manufacturers to request an exemption when an imported product meets an urgent U.S. health need.

The broader Section 232 policy imposes a 100% tariff on certain patented pharmaceuticals and associated ingredients, with the tariff scheduled to apply to companies not otherwise covered by earlier implementation provisions beginning September 29, 2026. Generic pharmaceutical products and associated ingredients are currently excluded from these Section 232 pharmaceutical tariffs.

Why It Matters:
The policy could affect the cost and availability of certain medications and pharmaceutical ingredients used in the United States. While LUGPA members are not directly responsible for paying these import tariffs in most cases, changes in manufacturers' costs and pharmaceutical supply chains could eventually affect drug acquisition costs, availability, and patient access.

Key Provisions

Commerce established a 0% tariff pathway for certain specialty products, including:

• Drugs for which all approved indications are designated as orphan;
• Nuclear medicines;
• Plasma-derived therapies;
• Fertility drugs;
• Cell and gene therapy products;
• Antibody-drug conjugates; and
• Certain medical countermeasures.

Products from specified jurisdictions can qualify for the zero-tariff treatment when the applicable conditions are met. Commerce also established a process for companies to request tariff relief when a specialty pharmaceutical meets an urgent U.S. health need.

The notice also creates a new HTSUS classification providing a 0% additional tariff for pharmaceutical products and associated ingredients used solely for clinical trials, research and development, or other non-commercial applications.

Potential Impact on LUGPA Members

The immediate impact on independent urology practices is likely to be limited. The notice primarily establishes rules for manufacturers, importers, and pharmaceutical supply chains, rather than physician practices.

However, the policy could have downstream implications for urology practices if tariffs increase the cost of imported products used in patient care. Potential effects include:

• Higher acquisition costs for certain physician-administered or specialty medications if manufacturers or distributors pass along increased costs.
• Supply-chain disruptions if tariffs affect sourcing of patented drugs or active pharmaceutical ingredients.
• Changes in manufacturer or distributor pricing that could affect the economics of administering certain therapies.
• Potential effects on patient access if higher costs or supply constraints affect the availability of particular treatments.

The impact will depend heavily on the specific drug, its patent status, country of origin, manufacturer, and whether it qualifies for one of the zero-tariff pathways. Generic drugs are currently outside the Section 232 pharmaceutical tariffs.

LUGPA Takeaway

This is primarily a pharmaceutical supply-chain and trade policy issue, rather than a direct physician-practice regulation. LUGPA will nevertheless monitor implementation because tariffs affecting imported pharmaceuticals and ingredients could affect drug costs, availability, and patient access, particularly for specialty therapies used in urology.

Source: Federal Register — Commerce Guidance on Specialty Pharmaceutical Tariff Adjustments